Publications (2)3.88 Total impact
-
Article: Hemangiopoietin supports animal survival and accelerates hematopoietic recovery of chemotherapy-suppressed mice.
[show abstract] [hide abstract]
ABSTRACT: To determine if recombinant human hemangiopoietin (HAPO), a novel growth factor for primitive cells of hematopoietic and endothelial cell lineages, accelerates hematopoietic reconstitution after high-dose chemotherapy in vivo in mice. Male Balb/c mice after treatment of 5-fluorouracil were subcutaneously injected with HAPO or its dilution for consecutive 10 d. Their survival and body weight together with peripheral blood were routinely tested. At day 7 and 14, the numbers of bone marrow (BM) cells as well as colony-forming units (CFU) after in vitro colony culture were counted. The peripheral blood CFU and the percentage of CD34+ CD117+ cells in BM were analyzed. Transwell chamber was used for cell migratory assay. HAPO at different doses significantly increased the survival rate and body weight, with an optimal effect in the HAPO 10 microg/d group. The number of BM cells and the percentage of CD34+ CD117+ cells were also increased after HAPO administration. The number of granulocyte/macrophage CFU and granulocyte, erythroid, macrophage and megakaryocyte CFU in BM after HAPO treatment was greater than that from the HAPO dilution group. More circulating CFU could be observed after injection of HAPO. In addition, this novel cytokine had a chemotactic effect on the hematopoietic stem/progenitor cells. HAPO improves animal survival and accelerates hematopoietic reconstitution of mice after high-dose chemotherapy.European Journal Of Haematology 01/2008; 79(6):477-85. · 2.61 Impact Factor -
Article: Survivin and leukemia.
[show abstract] [hide abstract]
ABSTRACT: Survivin is a unique member of the inhibitor-of-apoptosis family. Survivin plays a role in the proliferation and survival of normal hematopoietic cells. Survivin expression is aberrantly enhanced in most cancers and hematopoietic malignancies. Survivin is an attractive therapeutic target, and various approaches to targeting survivin have been tested in vitro and in vivo. We review here progress in survivin research.International Journal of Hematology 10/2004; 80(3):232-8. · 1.27 Impact Factor
